Used in conjunction with an oral anti-depressant for treatment resistant depression in adults (TRD). Spravato can only be administered at a
REMS (Risk Evaluation and Mitigation Strategy) certified treatment center.
The goal of the REMS is to mitigate risks and abuse and misuse of Spravato ensuring that Spravato is only dispensed and administered to patients in a medically supervised healthcare setting that monitors these patients.
Each patient is informed about possible adverse outcomes resulting
from sedation and disassociation and the need for monitoring.
Because of the possibility of delayed or prolonged sedation or
dissociation in some cases, patients must be monitored by a healthcare professional for at least 2 hours following each treatment session,
until the clinician determines the patient is safe to leave.
DOSING schedule INDUCTION:
Weeks 1-4 :starting dose 56mg or 84mg twice weekly
Weeks 5-8 :56mg or 84mg once weekly
Weeks 9 and after: ( weekly or every 2 weeks ) 56mg or 8mg
If doses are missed return to patients previous dosing schedule
(per clinical judgement)
Spravato is a schedule III controlled substance and may
be subject to abuse and diversion.
Before Administering SPRAVATO
The first and only NMDA receptor antagonist approved in conjunction with an oral AD for TRD in adults¹